

Southeastern Medical Device Association and Southeast BIO Merge to form Southeast Life Sciences

Merger of SEMDA and SEBIO results in single Southeastern platform for medtech, bioscience innovation, partnering and investor relations in region

ATLANTA, GEORGIA, USA, February 24, 2020 /EINPresswire.com/ --

Representatives from the Southeastern Medical Device Association (SEMDA) and Southeast BIO (SEBIO) have announced that the two organizations have officially merged to form [Southeast Life Sciences](#). The merger provides a single platform for medtech and bioscience innovation, partnering and investor relations in the region.



“

The convergence of medical technologies, including devices, with bioscience technologies including drugs, data, digital and combination products necessitates the convergence of these entities.”

Jason Rupp, Southeast Life Science Executive Director

“The convergence of medical technologies, including devices, with bioscience technologies including drugs, data, digital and combination products necessitates the convergence of these entities,” former SEMDA Executive Director and now Southeast Life Science Executive Director Jason Rupp says. “In order to respond to the combined needs of stakeholders in both ecosystems, the time has arrived for SEBIO and SEMDA to come together under one roof.”

Combining individuals, corporations, universities and other entities in one regional industry organization mitigates “death by one thousand conferences,” ensuring more efficient use of time and resources, Rupp says.

New technologies like nanoparticles and microneedles for drug delivery coming out of the Wallace H. Coulter Department of Biomedical Engineering, a joint program of Emory University and Georgia Tech, are tangible examples of the potential for innovation when multiple scientific disciplines connect.

“With the advent of devices like Cardiomems that blend device with data and devices that deliver pharmaceutical therapies, close connectivity between medical device and bioscience innovators is advantageous to regional stakeholders, especially investors,” Rupp says.

“Because clients span the entirety of medtech innovation including devices, pharmaceutical therapies and combination devices, many companies like ours needed to support both organizations,” says former SEMDA Chair Tiffany Wilson, CEO of the Global Center for Medical Innovation (GCMi). “Financially, this meant telling them, ‘We have this amount of funding support for you. You have to figure out how to divvy it up.’ While both SEBIO and SEMDA flagship conferences had value, bringing them under the same roof brings connectivity, educational and

financial efficiency gains for all concerned that should lift medtech and life science innovation and investment across the board.”

The inaugural [ADVANSE Life Science Conference](#), Southeast Life Science’s flagship event will be May 28-29, 2020 in [Charleston, SC](#). Organizers expect to convene more than 500 attendees, including a significant number of investors, highlighting innovations from 50 early stage medtech and bioscience companies over the two-day conference.

David Day, Executive Director of Southeast BIO, added, “Southeast BIO and SEMDA have been operating as sister organizations for medtech and life science stakeholders in the southeast. The resulting merger will provide a critical mass of innovation that will be more than the sum of its parts.”

Sam Patrick
Patrick Marketing
+1 864-787-0820

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2020 IPD Group, Inc. All Right Reserved.